Preventing chemotherapy-induced nausea and vomiting: the economic implications of choosing antiemetics

Vanscoy, Gordon J.; Fortner, Barry; Smith, Randall; Weber, Robert J.; Rihn, Thomas L.

doi:10.1016/s1548-5315(11)70865-8

Cited by 15 publications

(13 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a European study, across 208 cycles of moderately to highly emetogenic chemotherapy, the total cost of CINV prophylaxis and treatment was €53.62 35. In the US, costs are even higher; an office-based oncologist treating an episode of CINV incurred estimated labor costs of $US175 36. However, costs can be reduced through the prophylaxis of CINV.…”

Section: Resource Utilizationmentioning

confidence: 99%

Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting

Langford¹

2010

View full text Add to dashboard Cite

Introduction:The selective neurokinin-1 receptor antagonist aprepitant is effective in the treatment of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with both moderately and highly emetogenic chemotherapy. Fosaprepitant has been developed as an intravenous prodrug of aprepitant.Aims:To update the evidence underlying the use of fosaprepitant to prevent CINV.Evidence review:Aprepitant in combination with a serotonin antagonist and a corticosteroid controls acute and delayed symptoms of CINV in patients receiving moderately to highly emetogenic chemotherapy. Bioequivalence of fosaprepitant with aprepitant has recently been demonstrated, which has led to its inclusion in clinical guidelines for treatment of acute CINV with highly, and some regimens of moderately, emetogenic chemotherapy. Early studies of the clinical efficacy of fosaprepitant have shown improvement over treatment with ondansetron. Both aprepitant and fosaprepitant are well tolerated with most adverse events observed of mild or moderate intensity. Conflicting economic evidence has shown that whilst aprepitant provides an increased quality of life in patients treated for CINV, there are differing views over its absolute cost in relation to standard therapy. The incremental cost-effectiveness ratio of aprepitant, however, appears to lie within acceptable bounds.Place in therapy:Fosaprepitant and aprepitant are recommended in guidelines for preventing CINV due to moderately and highly emetogenic chemotherapy. Fosaprepitant is bioequivalent to aprepitant, and could offer potential benefits for patients who may be unable to tolerate oral administration of antiemetics during an episode of nausea or vomiting.

show abstract

Section: Resource Utilizationmentioning

confidence: 99%

Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting

Langford¹

2010

View full text Add to dashboard Cite

show abstract

“…Chemotherapy-induced nausea and vomiting (CINV) and its side effects imposes a burden on patients, clinicians, and the healthcare system (Vanscoy et al 2005; Wiser and Berger 2005). Of all the side effects of chemotherapy, CINV remains one of the most dreaded by patients (Sun et al 2004).…”

Section: The Burden Of Chemotherapy-induced Nausea and Vomitingmentioning

confidence: 99%

A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting

Ware¹

2008

TCRM

View full text Add to dashboard Cite

Chemotherapy-induced nausea and vomiting (CINV) in cancer patients places a signifi cant burden on patients' function and quality of life, their families and caregivers, and healthcare providers. Despite the advances in preventing CINV, a substantial proportion of patients experience persistent nausea and vomiting. Nabilone, a cannabinoid, recently received Food and Drug Administration approval for the treatment of the nausea and vomiting in patients receiving cancer chemotherapy who fail to achieve adequate relief from conventional treatments. The cannabinoids exert antiemetic effects via agonism of cannabinoid receptors (CB1 and CB2). Clinical trials have demonstrated the benefi ts of nabilone in cancer chemotherapy patients. Use of the agent is optimized with judicious dosing and selection of patients.

show abstract

“…The corresponding values placed on a decrease in delayed emesis of 30% were $US50, $US41, $US31, and $US9 per day for 4 days. (Vanscoy et al 2005). This difference of $US23 represents net revenue for a practice, but does not include costs associated with rent or other overheads, indicating the potential economic impact of an uncontrolled episode of CINV at this level.…”

Section: Economic Evidencementioning

confidence: 99%

Aprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting

Chrisp¹

2007

View full text Add to dashboard Cite

Preventing chemotherapy-induced nausea and vomiting: the economic implications of choosing antiemetics

Cited by 15 publications

References 6 publications

Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting

Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting

A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting

Aprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting

Contact Info

Product

Resources

About